&NA;ABT 627 (A147627, ABT 147627) is a selective endothelin-A (ET-A) antagonist. It is the active enantiomer of the racemate, A127722. It is about 1000-fold selective for the ET-A versus endothelin-B receptor.ABT 627 is undergoing phase I clinical trials in the US for the treatment of coronary disorders and refractory adenocarcinomas and phase II trials for prostate cancer. It may have potential in the prevention and/or treatment of coronary restenosis after percutaneous revascularisation with stents.